The Insulin Cost Reduction Act

Bill: 117-hr-5623
Sponsor: full_name: Rep. Grothman, Glenn [R-WI-6]
Introduced: 2021-10-19
Policy area: Health
Latest action: action_date: 2021-10-20
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2021-10-19
action_desc: Introduced in House
text: <p><b>The Insulin Cost Reduction Act</b></p> <p>This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 5623 IN THE HOUSE OF REPRESENTATIVES October 19, 2021 Mr. Grothman introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XVIII of the Social Security Act to prohibit price concessions with respect to insulin drugs and exceptions under part D of Medicare, and for other purposes.

1. Short title This Act may be cited as the The Insulin Cost Reduction Act . 2. Prohibition of price concessions with respect to insulin drugs and exceptions under part D of Medicare (a) In general Section 1860D–2(d)(1) of the Social Security Act ( 42 U.S.C. 1395w–102(d)(1) ) is amended— (1) in subparagraph (A), by striking Under and inserting Subject to subparagraph (D), under ; and (2) by adding at the end the following new subparagraph: (D) Prohibition of price concessions with respect to insulin drugs and exceptions For plan years beginning 180 days after the date of the enactment of this subparagraph, no price concessions negotiated between manufacturers and a prescription drug plan or MA–PD plan shall be permitted with respect to an insulin drug (as determined by the Secretary), unless— (i) such price concessions provided under such a plan shall be provided to enrollees of such a plan at pharmacies or by mail order service at the point-of-sale of such insulin drugs; or (ii) the cost-sharing required with respect to such insulin drugs shall be calculated in a manner that takes into account any amounts received pursuant to such price concessions. .